Development and Validation of 11 Symptom Indexes to Evaluate Response to Chemotherapy for Advanced Cancer

Restricted access

Recent guidance from the FDA discusses patient-reported outcomes as end points in clinical trials. Using methods consistent with this guidance, the authors developed symptom indexes for patients with advanced cancer. Input on the most important symptoms was obtained from 533 patients recruited from NCCN Member Institutions and 4 nonprofit social service organizations. Diagnoses included bladder, brain, breast, colorectal, head and neck, hepatobiliary/pancreatic, kidney, lung, ovarian, and prostate cancers and lymphoma. Physician experts in each of these diseases were also surveyed to differentiate symptoms that were predominantly disease-based from those that were predominantly treatment-induced. Results are evaluated alongside previously published indexes for 9 of these 11 advanced cancers that were created based on expert provider surveys, also implemented at NCCN Member Institutions. Final results are 11 symptom indexes that reflect the highest priorities of people affected by these 11 advanced cancers and the experienced perspective of the people who provide their medical treatment. Beyond the clinical value of such indexes, they may also contribute significantly to satisfying regulatory requirements for a standardized tool to evaluate drug efficacy with respect to symptomatology.

Correspondence: David Cella, PhD, Robert H. Lurie Comprehensive Cancer Center, Department of Medical Social Sciences, Northwestern University, 710 N Lake Shore Drive – 7th Floor, Chicago, IL 60611. E-mail: d-cella@northwestern.edu
  • 1.

    Guidance for Industry: patient-reported outcome measures: use in medical product development to support labeling claims. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed January 20, 2011.

    • Search Google Scholar
    • Export Citation
  • 2.

    Cella DF, Paul D, Yount S. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest 2003;21:526535.

    • Search Google Scholar
    • Export Citation
  • 3.

    Aaronson NK, Ahmedzai S, Bergman B. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365376.

    • Search Google Scholar
    • Export Citation
  • 4.

    Cella DF, Tulsky DS, Gray G. The Functional Assessment of Cancer Therapy (FACT) Scale: development and validation of the general measure. J Clin Oncol 1993;11:570579.

    • Search Google Scholar
    • Export Citation
  • 5.

    Cella DF, Bonomi AE. Measuring quality of life: 1995 update. Oncology 1995;9(Suppl):4760.

  • 6.

    Schag CA, Heinrich RL. Development of a comprehensive quality of life measurement tool: CARES. Oncology (Williston Park) 1990;4:135138.

  • 7.

    Schipper H, Clinch J, McMurray A. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 1984;2:472483.

    • Search Google Scholar
    • Export Citation
  • 8.

    Taylor KM, Macdonald KG, Bezak A. Physicians' perspective on quality of life: an exploratory study of oncologists. Qual Life Res 1996;5:514.

    • Search Google Scholar
    • Export Citation
  • 9.

    Bezjak A, Taylor KM, Ng P. Quality-of-life information and clinical practice: the oncologist's perspective. Cancer Prev Control 1998;2:230235.

    • Search Google Scholar
    • Export Citation
  • 10.

    Deyo RA, Patrick DL. Barriers to the use of health status measures in clinical investigation, patient care, and policy research. Med Care 1989;27(Suppl):S254268.

    • Search Google Scholar
    • Export Citation
  • 11.

    Nelson EC, Berwick DM. The measurement of health status in clinical practice. Med Care 1989;27(Suppl):S7790.

  • 12.

    Fish LS, Lewis BE. Quality of life issues in the management of ovarian cancer. Semin Oncol 1999;26(Suppl 1):3239.

  • 13.

    Morris J, Perez D, McNoe B. The use of quality of life data in clinical practice. Qual Life Res 1998;7:8591.

  • 14.

    Browman GP. Science, language, intuition, and the many meanings of quality of life. J Clin Oncol 1999;17:16511653.

  • 15.

    Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994;32:619626.

  • 16.

    Guyatt G, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;32:622629.

  • 17.

    Hopwood P. Progress, problems, and priorities in quality of life research. Eur J Cancer 1992;28A:17481752.

  • 18.

    Skeel R. Quality of life dimensions that are most important to cancer patients. Oncology 1993;32:5570.

  • 19.

    Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA 1995;32:5965.

    • Search Google Scholar
    • Export Citation
  • 20.

    Rothermich EA, Pathak DS. References for health-related quality of life claims in prescription drug advertisements. Am J Health Syst Pharm 1997;32:25962599.

    • Search Google Scholar
    • Export Citation
  • 21.

    F-D-C Report: ``The Pink Sheet.''. Quality of life ad claims should be specific, FDA-sponsored physician focus groups say: ad division direction cautions against QOL ``claim expansiveness.'' 1994;32:89.

    • Search Google Scholar
    • Export Citation
  • 22.

    Beitz J. Quality-of-life end points in oncology drug trials. Oncology 1999;32:14391447.

  • 23.

    Quality Of Life Subcommittee of the Oncologic Drugs Advisory Committee, February 10, 2000. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/ohrms/dockets/ac/00/slides/3591s1.htm. Accessed January 20, 2011.

    • Search Google Scholar
    • Export Citation
  • 24.

    Leidy NK, Revicki DA, Genesté B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999;32:113127.

    • Search Google Scholar
    • Export Citation
  • 25.

    Portenoy RK, Thaler HT, Kornblith AB. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 1994a;3:183189.

    • Search Google Scholar
    • Export Citation
  • 26.

    Portenoy RK, Thaler HT, Kornblith AB. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994b;30A:13261336.

    • Search Google Scholar
    • Export Citation
  • 27.

    Coons SJ, Kaplan RM. Assessing health-related quality of life: application to drug therapy. Clin Ther 1992;32:850858.

  • 28.

    Sutherland HJ, Lockwood GA, Boyd NF. Ratings of the importance of quality of life variables: therapeutic implications for patients with metastatic breast cancer. J Clin Epidemiol 1990;32:661666.

    • Search Google Scholar
    • Export Citation
  • 29.

    Kong S, Gandhi SK. Methodologic assessments of quality of life measures in clinical trials. Ann Pharmacother 1997;32:830836.

  • 30.

    Brunelli C, Costantini M, Di Giulio P. Quality of life evaluation: when do terminal cancer patients and health-care providers agree? J Pain Symptom Manage 1998;32:151158.

    • Search Google Scholar
    • Export Citation
  • 31.

    Justice AC, Rabeneck L, Hays RD. Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. J AIDS 1999;32:126133.

    • Search Google Scholar
    • Export Citation
  • 32.

    Nekolaichuk C, Bruera E, Spachynski K. A comparison of patient and proxy symptom assessments in advanced cancer patients. Palliat Med 1999;32:311323.

    • Search Google Scholar
    • Export Citation
  • 33.

    Stephens RJ, Hopwood P, Girling DJ. Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 1997;32:225236.

    • Search Google Scholar
    • Export Citation
  • 34.

    Stromgren AS, Groenvold M, Sorensen A. Symptom recognition in advanced cancer: a comparison of nursing records against patient self-rating. Acta Anaesthesiol 2001;32:10801085.

    • Search Google Scholar
    • Export Citation
  • 35.

    Lampic C, Nordin K, Sjoden P. Agreement between cancer patients and their physicians in the assessment of patient anxiety at follow-up visits. Psychooncology 1995;32:301310.

    • Search Google Scholar
    • Export Citation
  • 36.

    Passik SD, Dugan W, McDonald MV. Oncologists' recognitions of depression in their patients with cancer. J Clin Oncol 1998;32:15941600.

  • 37.

    Rao D, Butt Z, Rosenbloom S. A comparison of the Renal Cell Carcinoma Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Pain Symptom Manage 2009;32:291298.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 96 82 3
PDF Downloads 19 16 1
EPUB Downloads 0 0 0